Published in Am J Cardiol on September 01, 1979
P-wave dispersion and heart rate variability in children with mitral valve prolapse. Pediatr Cardiol (2011) 0.91
Echocardiographic AV-interval optimization in patients with reduced left ventricular function. Cardiovasc Ultrasound (2004) 0.91
Atrial electromechanical sequence in normal subjects and patients with DDD pacemakers. Br Heart J (1995) 0.81
Utilization of Electrocardiographic P-wave Duration for AV Interval Optimization in Dual-Chamber Pacemakers. Indian Pacing Electrophysiol J (2010) 0.77
Simulated Obstructive Sleep Apnea Increases P-Wave Duration and P-Wave Dispersion. PLoS One (2016) 0.76
Prevalence of E/A wave fusion and A wave truncation in DDD pacemaker patients with complete AV block under nominal AV intervals. PLoS One (2015) 0.75
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation (1990) 2.22
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
Fatal hemorrhage as a complication of neurofibromatosis. Vasc Surg (1972) 1.67
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 1.63
Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol (1984) 1.57
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation (1983) 1.51
Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol (1990) 1.44
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation (1978) 1.35
Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol (1986) 1.32
Inferior and anteroseptal myocardial infarction concealed by transient left anterior hemiblock. J Electrocardiol (1973) 1.32
Aorto-left atrial fistula. A reversible cause of acute refractory heart failure. Chest (1997) 1.23
Human myocardial histologic characteristics in congestive heart failure. Circulation (1983) 1.23
The "holiday heart": electrophysiologic studies of alcohol effects in alcoholics. Ann Intern Med (1983) 1.22
The arrhythmogenic effects of caffeine in human beings. N Engl J Med (1983) 1.22
Cocaine-induced coronary-artery dissection. N Engl J Med (1994) 1.21
Prolonged atrial conduction. A major predisposing factor for the development of atrial flutter. Circulation (1978) 1.20
Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation (1984) 1.18
Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med (1980) 1.17
Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med (1984) 1.16
Protective influence of cardiac denervation against arrhythmias of myocardial infarction. Cardiovasc Res (1969) 1.15
The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation (1977) 1.15
Altered collagen composition in a prolapsing mitral valve with ruptured chordae tendineae. Am J Med (1979) 1.12
Sleep apnea: treatment with protriptyline. Neurology (1979) 1.12
Captopril in primary pulmonary hypertension. Circulation (1983) 1.12
Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation (1979) 1.12
Cardiovascular effects of ophthalmic timolol. Ann Intern Med (1986) 1.10
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol (1993) 1.09
Hemodynamic changes after meals and placebo treatment in chronic congestive heart failure. Am J Cardiol (1986) 1.07
Treatment of ventricular arrhythmia by permanent atrial pacemaker and cardiac sympathectomy. Ann Intern Med (1968) 1.05
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. Ann Intern Med (1982) 1.04
The spectrum of cardiac defects in the Ehlers-Danlos syndrome, types I and III. Ann Intern Med (1980) 1.04
The hemodynamic effects of ibopamine, a dopamine congener, in patients with congestive heart failure. Pharmacotherapy (1986) 1.02
Drugs five years later. Dobutamine. Ann Intern Med (1983) 1.02
Coronary collateral vessels: spectrum of physiologic capabilities with respect to providing rest and stress myocardial perfusion, maintenance of left ventricular function and protection against infarction. Am J Cardiol (1982) 1.02
Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. Ann Intern Med (1981) 1.01
Dissimilar atrial rhythms. A patient with interatrial block. Br Heart J (1977) 1.01
Physiological adjustments to higher- or lower-intensity exercise in elders. Med Sci Sports Exerc (1983) 1.01
Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol (1998) 0.96
Persistent left superior vena cava: unusual wave contour of left jugular vein as the presenting feature. Am Heart J (1990) 0.96
Clinical experience and grading of amiodarone keratopathy. Ophthalmology (1984) 0.95
Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol (1984) 0.93
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol (1994) 0.93
The noninvasive localization of ventricular pacing sites by radionuclide phase imaging. Circulation (1984) 0.92
Nitrate tolerance. Am Heart J (1985) 0.92
Effects of digitalis on the functional refractory period of the AV node: studies in awake dogs with and without cardiac denervation. Cardiovasc Res (1968) 0.92
Cardiac catheterization and coronary angiography using 5 French preformed (Judkins) catheters from the percutaneous right brachial approach: a comparative analysis with the femoral approach. Cathet Cardiovasc Diagn (1993) 0.91
Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure. Circulation (1989) 0.91
The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J (1983) 0.90
Hemodynamic-inotropic response to beta-blocker with intrinsic sympathomimetic activity in patients with congestive cardiomyopathy. Circulation (1986) 0.89
Familial right bundle-branch block, left axis deviation, complete heart block, and early death. A heritable disorder of cardiac conduction. Ann Intern Med (1973) 0.89
Early changes in human myocardial nuclei after doxorubicin. Cancer (1983) 0.88
The effect of left atrial histology and dimension on P wave morphology. J Electrocardiol (1983) 0.88
Mitral valve prolapse: cardiac arrest with long-term survival. Int J Cardiol (1990) 0.88
Effect of increased adrenergic activity on the relationship between electrical and mechanical systole. Circulation (1981) 0.88
Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep (1982) 0.87
Factors determining vulnerability to ventricular fibrillation induced by 60-CPS alternating current. Circ Res (1967) 0.87
Superiority of 24-hour outpatient monitoring over multi-stage exercise testing for the evaluation of syncope. J Electrocardiol (1979) 0.87
Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation. Pacing Clin Electrophysiol (1999) 0.86
The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med (1991) 0.86
Central and regional hemodynamic effects of flosequinan for congestive heart failure. Am J Cardiol (1989) 0.86
Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. Am J Cardiol (1980) 0.86
Doxorubicin cardiotoxicity. Cancer Treat Rev (1982) 0.86
Postoperative pericarditis following thymectomy for myasthenia gravis. A prospective study. Chest (1983) 0.86
Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. J Pharmacol Exp Ther (1984) 0.85
Rest and exercise cardiovascular effects of terazosin in congestive heart failure. Am J Cardiol (1990) 0.85
Hemodynamic correlates for timing intervals, ejection rate and filling rate derived from the radionuclide angiographic volume curve. Am J Cardiol (1984) 0.84
Cardiac function in Duchenne's muscular dystrophy. Results of 10-year follow-up study and noninvasive tests. Am J Med (1982) 0.84
Drug-induced conditioning in congestive heart failure. Circulation (1982) 0.84
Temporary atrial standstill. Am Heart J (1979) 0.83
Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol (1996) 0.83
Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 0.83
Negative inotropic effect of lidocaine in patients with coronary arterial disease and normal subjects. Chest (1977) 0.83
Placebo treatment in congestive heart failure. Cardiology (1992) 0.83
Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J (1980) 0.83
Provocation of ventricular tachycardia after consumption of alcohol. N Engl J Med (1979) 0.83
An electrophysiologic study of swallowing-induced tachycardia. Chest (1978) 0.83
Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias. Ann Intern Med (1990) 0.82
The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J (1983) 0.82